✓
Open
30 Jul to 1 Aug, 2024
✓
Close
30 Jul to 1 Aug, 2024
3
Allotment
—
✓
Listing
Tue, Aug 6, 2024
Price Band
₹646 to ₹679
Issue Size
2,73,68,143 shares (agg. up to ₹1,857 Cr)
Lot Size
22 Shares
Listing Date
Tue, Aug 6, 2024
Latest GMP
₹43
Est. Gain
6.33%
✦ AI Insight
GMP Trend
06-08-2024₹43Est. ₹722+6.33%
05-08-2024₹43Est. ₹722+6.33%
04-08-2024₹86Est. ₹765+12.67%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 35.54x |
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Assets | 3,516.37 | 3,266.53 | 3,069.05 |
| Total Income | 4,212.21 | 3,700.93 | 3,694.52 |
| Profit After Tax | 0.79 | 97.82 | -250.87 |
| NET Worth | 709.50 | 717.19 | 621.98 |
| Reserves and Surplus | 861.01 | 868.70 | 787.79 |
| Total Borrowing | 491.56 | 536.97 | 357.95 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals Ltd. | Mainboard | ₹1,952.03 Cr | ₹1008 | 34.55 | ₹1,359.15 | +34.84% | ₹1,802.70 (+0.61%) |
| Innova Captab Ltd. | Mainboard | ₹570.00 Cr | ₹448 | 31.64 | ₹541.40 | +20.85% | ₹1,011.30 (+2.04%) |
| Blue Jet Healthcare Ltd. | Mainboard | ₹840.27 Cr | ₹346 | 37.49 | ₹413.40 | +19.48% | ₹588.15 (-1.65%) |
| Valiant Laboratories Ltd. | Mainboard | ₹152.46 Cr | ₹140 | 15.71 | ₹170.25 | +21.61% | ₹63.60 (-1.68%) |
| Concord Biotech Ltd. | Mainboard | ₹1,550.52 Cr | ₹741 | 32.29 | ₹942.80 | +27.23% | ₹1,346.00 (+0.23%) |
| Medicamen Organics Ltd. | SME | ₹10.54 Cr | ₹34 | 30.53 | ₹144.70 | +325.59% | ₹23.00 (-1.50%) |
| Quest Laboratories Ltd. | SME | ₹43.16 Cr | ₹97 | 23.03 | ₹147.35 | +51.91% | ₹96.95 (+8.08%) |
| Zenith Drugs Ltd. | SME | ₹40.68 Cr | ₹79 | 18.4 | ₹105.15 | +33.10% | ₹50.10 (-4.48%) |
| Sunrest Lifescience Ltd. | SME | ₹10.85 Cr | ₹84 | 12.33 | ₹79.80 | -5.00% | ₹35.00 (-1.69%) |
| Mono Pharmacare Ltd. | SME | ₹14.84 Cr | ₹28 | null | ₹30.45 | +8.75% | ₹10.75 (+4.88%) |
| Shelter Pharma Ltd. | SME | ₹16.03 Cr | ₹42 | 5.62 | ₹41.96 | -0.10% | ₹26.00 (+1.96%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment/prepayment of all or certain borrowings of our Company | 159.91 |
| 2 | Repayment/prepayment of all or certain borrowings of our Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited | 227.09 |
| 3 | Funding incremental working capital requirements of our Company | 55.00 |
| 4 | Pursuing inorganic growth initiatives through acquisitions | 27.87 |
| 5 | General corporate purposes | 167.50 |
About Akums Drugs IPO
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs). As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few. The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of
Contact Details
Akums Drugs & Pharmaceuticals Ltd. Address304, Mohan PlaceLSC Saraswati ViharDelhi, New Delhi, 110034+91 11 6904 1000cs@akums.netVisit Website